Stocks Health care EDSA
NASDAQ · Health careEdesa Biotech, Inc. (EDSA)
It posted a net loss of $14.1M. At June 30, 2026 it held $10.3M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
Key facts about Edesa Biotech, Inc.
- Net worth
- Edesa Biotech, Inc. has a market value (market cap) of $19.5M at the latest share price, and shareholders' equity of $8.8M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2021 revenue was $0 (-100.0% year on year), with a net loss of $13.3M.
- Cash flow
- In fiscal 2025 operations used $7.3M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 13, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Edesa Biotech, Inc.'s next report is expected around December 11, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Edesa Biotech, Inc. does
Edesa Biotech, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker EDSA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$7.2M | -$1.27 | n/a |
| 2024 | n/a | -$6.2M | -$1.93 | n/a |
| 2023 | n/a | -$8.4M | -$2.93 | -$6.6M |
| 2022 | n/a | -$17.5M | n/a | -$12.3M |
| 2021 | $0 | -$13.3M | -$1.10 | -$13.7M |
| 2020 | $328.8K | -$6.4M | -$0.74 | -$5M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Edesa Biotech, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 26, 2026Passive stake (5% or more) SCHEDULE 13G
- August 25, 2026Activist stake changed SCHEDULE 13D/A
- August 25, 2026Activist stake changed SCHEDULE 13D/A
- August 20, 2026
- August 13, 2026
- August 13, 2026
- July 2, 2026
- June 18, 2026Passive stake (5% or more) SCHEDULE 13G
- June 16, 2026Activist stake changed SCHEDULE 13D/A
- June 11, 2026
Insider trades
What the people running Edesa Biotech, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 2 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 5, 2026 | Nijhawan PardeepChief Executive Officer, Director, 10% owner | Received as pay | 6,893 | - |
| September 1, 2026 | Nijhawan PardeepChief Executive Officer, Director, 10% owner | Received as pay | 5,714 | - |
| August 3, 2026 | Nijhawan PardeepChief Executive Officer, Director, 10% owner | Received as pay | 5,324 | - |
| July 2, 2026 | Nijhawan PardeepChief Executive Officer, Director, 10% owner | Received as pay | 3,378 | - |
| June 16, 2026 | Nijhawan PardeepChief Executive Officer, Director, 10% owner | Received as pay | 153,550 | $800K |
| June 1, 2026 | Nijhawan PardeepChief Executive Officer, Director, 10% owner | Received as pay | 1,671 | - |
| May 27, 2026 | Liu Da DavidDirector | Received as pay | 19,000 | - |
| May 27, 2026 | Nijhawan PardeepChief Executive Officer, Director, 10% owner | Received as pay | 96,913 | - |
Who owns EDSA
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Pardeep Nijhawan13D, may seek influence with 4 related filers | 16.31% | August 25, 2026 |
| Velan Capital Investment Management LP13D, may seek influence with 8 related filers | 9.99% | August 25, 2026 |
| Rubric Capital Management LP13G, passive with 1 related filers | 7.74% | May 15, 2026 |
| Sirenia Capital Management LP13G, passive with 1 related filers | 7.2% | May 15, 2026 |
| Stonepine Capital Management, LLC13G, passive with 3 related filers | 6.9% | August 26, 2026 |
| Perceptive Advisors LLC13G, passive with 2 related filers | 6.7% | March 16, 2026 |
| Integrated Core Strategies (US) LLC13G, passive with 3 related filers | 5.4% | June 18, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 33 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Velan Capital Investment Management LP | 827,500 | 0 |
| Rubric Capital Management LP | 669,500 | -18,000 |
| Perceptive Advisors LLC | 563,239 | 0 |
| Millennium Management LLC | 561,751 | new |
| Stonepine Capital Management, LLC | 456,439 | +426,439 |
| Boxer Capital Management, LLC | 205,000 | new |
| Vanguard Capital Management LLC | 81,839 | -4,127 |
| Geode Capital Management, LLC | 80,879 | +3,825 |
| Jane Street Group, LLC | 72,465 | -43,256 |
| Vanguard Fiduciary Trust Co | 38,718 | +272 |
| State Street Corp | 37,979 | 0 |
| XTX Topco Ltd | 35,352 | new |
| BlackRock, Inc. | 27,495 | -214 |
| Northern Trust Corp | 14,994 | 0 |
| Scotia Capital Inc. | 14,393 | -1,450 |
| Two Sigma Investments, LP | 14,032 | new |
| UBS Group AG | 6,763 | +4,420 |
| SBI Securities Co., Ltd. | 3,505 | +3 |
| Federation des caisses Desjardins du Quebec | 2,595 | new |
| Royal Bank of Canada | 1,851 | +192 |
Insiders
9 insiders reported holding 1,976,450 shares in total, about $4M at the last price.
| Holder | Shares |
|---|---|
| Nijhawan PardeepChief Executive Officer, Director, 10% owner | 1,308,695402,702 held indirectly |
| Brooks Michael JPresident | 291,479 |
| Weiler Peter J.Chief Financial Officer | 129,609 |
| Marshall PatrickDirector | 71,666 |
| Sistilli CarloDirector | 49,417 |
| MacDonald Sean ArthurDirector | 41,054 |
| Chypyha JoanDirector | 30,029 |
| Olson Charles VDirector | 30,000 |
| Liu Da DavidDirector | 24,501 |
Questions about EDSA
What does Edesa Biotech, Inc. do?
Edesa Biotech, Inc. is a company in the Health care sector, listed on NASDAQ as EDSA. Its shares trade on NASDAQ under the ticker EDSA.
What is Edesa Biotech, Inc.'s net worth?
Edesa Biotech, Inc. has a market value (market cap) of $19.5M at the latest share price, and shareholders' equity of $8.8M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Edesa Biotech, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $14.1M.
When did Edesa Biotech, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from October 6, 2026.
When is Edesa Biotech, Inc.'s next earnings report?
Edesa Biotech, Inc.'s next report is expected around December 11, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare EDSA with
Follow EDSA
Get an email when Edesa Biotech, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Edesa Biotech, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.